Tiziana Life Sciences Ltd (TLSA)

NASDAQ: TLSA · IEX Real-Time Price · USD
0.760
+0.026 (3.51%)
At close: Aug 19, 2022 3:55 PM
0.760
0.000 (0.026%)
After-hours: Aug 19, 2022 4:54 PM EDT
3.51%
Market Cap 77.71M
Revenue (ttm) n/a
Net Income (ttm) -23.42M
Shares Out 102.27M
EPS (ttm) -0.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 75,186
Open 0.712
Previous Close 0.734
Day's Range 0.712 - 0.760
52-Week Range 0.530 - 2.100
Beta -0.02
Analysts Buy
Price Target 4.93 (+548.9%)
Earnings Date Aug 19, 2022

About TLSA

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases... [Read more...]

Industry Biotechnology
IPO Date Mar 24, 2000
Employees 14
Stock Exchange NASDAQ
Ticker Symbol TLSA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for TLSA stock is "Buy." The 12-month stock price forecast is 4.93, which is an increase of 548.85% from the latest price.

Price Target
$4.93
(548.85% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman

NEW YORK, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug ...

Tiziana Life Sciences Announces Presentation at Alzheimer's Association International Conference® 2022 (AAIC®) Evalua...

Study conducted in animal models of Alzheimer's disease finds restored microglia homeostasis and improvement in cognition Study conducted in animal models of Alzheimer's disease finds restored microglia...

Tiziana Life Sciences Appoints Matthew W. Davis, MD, RPh as Chief Medical Officer and Acting Chief Scientific Officer

NEW YORK, July 18, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug...

Tiziana Life Sciences Announces Resignation of CEO

NEW YORK, July 15, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug ...

Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice

NEW YORK, June 17, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq:  TLSA ) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of monoclo...

Tiziana Life Sciences Announces An Interview on Clinical Improvements for 2nd SPMS Patient

NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug admi...

Tiziana Life Sciences Shares Jump After Multiple Sclerosis Data From Second Patient

Tiziana Life Sciences (NASDAQ: TLSA) reported clinical results from the second patient with Secondary Progressive Multiple Sclerosis (SPMS) in the ongoing study as part of an expanded access program. Th...

Tiziana Life Sciences Announces Positive Clinical Results in the Second Patient with Secondary Progressive Multiple S...

NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug admi...

Tiziana Life Sciences to Present at the 2022 Biotechnology Innovation Organization Annual Convention to Discuss Recen...

NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical company enabling breakthrough immunotherapies via no...

Data from Secondary Progressive Multiple Sclerosis Patient Treated with Intranasal Treatment with Foralumab will be P...

NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq:  TLSA ) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of monoclo...

Tiziana Life Sciences Ltd. Announces Annual Report Filed to Regain Nasdaq Compliance

Form 20-F Filed on May 23, 2022 Following Receipt of Notice from Nasdaq Regarding Filing Deadline of its Annual Report Form 20-F Filed on May 23, 2022 Following Receipt of Notice from Nasdaq Regarding F...

Tiziana Life Sciences to participate in a Fireside Chat At the B. Riley Securities 2022 Virtual Neuro & Ophthalmology...

NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical company developing alternative routes of immunother...

FDA Grants Permission to Enroll up to 8 Additional Secondary Progressive Multiple Sclerosis (SPMS) Patients in the Ex...

NEW YORK, April 05, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq:  TLSA ) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of monocl...

Tiziana Announces Initiation of Phase 1b Clinical Trial in Crohn's Disease Patients to Evaluate Oral Capsules of Fora...

NEW YORK, March 25, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of monoclon...

Tiziana Announces Availability of March 14 KOL Event Replay

NEW YORK, March 15, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug del...

Tiziana Life Sciences Hosting Key Opinion Leader Virtual Event to Discuss the Intranasal Delivery of Foralumab in Mul...

Monday, March 14th @ 11 am ET, registration details below Monday, March 14th @ 11 am ET, registration details below

Tiziana Life Shares Rise On Encouraging Data From Intranasal Foralumab In Multiple Sclerosis Patient

Tiziana Life Sciences Ltd (NASDAQ: TLSA) has reported clinical data in a patient with Secondary Progressive Multiple Sclerosis (SPMS) following six months of treatment with intranasally administered for...

Top Penny Stocks Today: Why PT, TLSA, AGRI and HTCR Are Up Thursday

Penny stocks are on the move today with some of the top companies in the space seeing major movement alongside heavy trading of their shares. The post Top Penny Stocks Today: Why PT, TLSA, AGRI and HTCR...

Other symbols: AGRIHTCRPT

Tiziana Announces Positive Clinical Data from A Secondary Progressive Multiple Sclerosis Patient Treated for Six Mont...

NEW YORK, March 10, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug del...

StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort

NEW YORK, March 01, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.'s (Nasdaq: TLSA) former subsidiary, AccuStem Sciences, Inc. (OTC PINK: ACMSY) (formerly AccuStem Sciences Ltd.), today announced p...

Tiziana Life Sciences CEO to Present at Annual BIO CEO & Investor Conference

NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug ...

Tiziana Announces Submission of Amendment to Investigational New Drug Application to Advance Oral Foralumab, a Fully ...

- Tiziana is Developing the First Oral Form of Foralumab in a Convenient Capsule to be Evaluated in Phase 1b Clinical Study

Tiziana Life Sciences to participate in a Fireside Chat At the B. Riley Securities 2022 Oncology Conference

NEW YORK, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical company developing breakthrough therapies for KRAS+ ...